Published in PLoS One on September 02, 2013
Accurate pan-specific prediction of peptide-MHC class II binding affinity with improved binding core identification. Immunogenetics (2015) 0.93
Identification and HLA-tetramer-validation of human CD4+ and CD8+ T cell responses against HCMV proteins IE1 and IE2. PLoS One (2014) 0.82
HIV controllers exhibit enhanced frequencies of MHC class II tetramer+ Gag-specific CD4+ T cells in chronic clade C HIV-1 infection. J Virol (2017) 0.76
Evolution of MHC-based technologies used for detection of antigen-responsive T cells. Cancer Immunol Immunother (2017) 0.75
A Diverse Repertoire of CD4 T Cells Targets the Immediate-Early 1 Protein of Human Cytomegalovirus. Front Immunol (2015) 0.75
Phenotypic analysis of antigen-specific T lymphocytes. Science (1996) 24.26
Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol (2010) 11.80
Two populations of Ia-like molecules on a human B cell line. J Immunol (1980) 7.68
Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes. Immunity (1998) 4.15
A kinetic basis for T cell receptor repertoire selection during an immune response. Immunity (1999) 3.88
MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen. J Clin Invest (1999) 3.83
Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Invest (2003) 3.40
Virus-specific CD4(+) memory-phenotype T cells are abundant in unexposed adults. Immunity (2013) 3.38
HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature (1992) 2.54
Initiation of signal transduction through the T cell receptor requires the multivalent engagement of peptide/MHC ligands [corrected]. Immunity (1998) 2.52
Frequency of epitope-specific naive CD4(+) T cells correlates with immunodominance in the human memory repertoire. J Immunol (2012) 2.09
Human TCR-binding affinity is governed by MHC class restriction. J Immunol (2007) 2.02
Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol (1997) 1.98
Tricks with tetramers: how to get the most from multimeric peptide-MHC. Immunology (2009) 1.78
HLA class II-restricted CD4+ T cell responses directed against influenza viral antigens postinfluenza vaccination. J Immunol (2003) 1.69
One-pot, mix-and-read peptide-MHC tetramers. PLoS One (2008) 1.50
Class II major histocompatibility complex tetramer staining: progress, problems, and prospects. Immunology (2008) 1.47
Use of soluble peptide-DR4 tetramers to detect synovial T cells specific for cartilage antigens in patients with rheumatoid arthritis. Proc Natl Acad Sci U S A (2000) 1.46
Selective activation and expansion of high-affinity CD4+ T cells in resistant mice upon infection with Leishmania major. Immunity (2000) 1.46
MHC class II tetramers. J Immunol (2012) 1.45
Functional avidity directs T-cell fate in autoreactive CD4+ T cells. Blood (2005) 1.39
Peptide binding to HLA class I molecules: homogenous, high-throughput screening, and affinity assays. J Biomol Screen (2009) 1.27
Cutting edge: detection of antigen-specific CD4+ T cells by HLA-DR1 oligomers is dependent on the T cell activation state. J Immunol (2001) 1.27
Efficient assembly of recombinant major histocompatibility complex class I molecules with preformed disulfide bonds. Eur J Immunol (2001) 1.19
New design of MHC class II tetramers to accommodate fundamental principles of antigen presentation. J Immunol (2009) 1.18
Structural analysis of a peptide--HLA class II complex: identification of critical interactions for its formation and recognition by T cell receptor. Int Immunol (1989) 1.18
Potent T cell activation with dimeric peptide-major histocompatibility complex class II ligand: the role of CD4 coreceptor. J Exp Med (1998) 1.16
Purification of correctly oxidized MHC class I heavy-chain molecules under denaturing conditions: a novel strategy exploiting disulfide assisted protein folding. Protein Sci (2003) 1.16
HLA-DQ tetramers identify epitope-specific T cells in peripheral blood of herpes simplex virus type 2-infected individuals: direct detection of immunodominant antigen-responsive cells. J Immunol (2000) 1.14
Amino-terminal flanking residues determine the conformation of a peptide-class II MHC complex. J Immunol (2006) 1.09
A strategy to determine HLA class II restriction broadly covering the DR, DP, and DQ allelic variants most commonly expressed in the general population. Immunogenetics (2013) 1.04
Functional recombinant MHC class II molecules and high-throughput peptide-binding assays. Immunome Res (2009) 1.03
Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers. Proc Natl Acad Sci U S A (2010) 0.99
MHC II tetramers visualize human CD4+ T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response. J Exp Med (2013) 0.97
HLA-DR alpha chain residues located on the outer loops are involved in nonpolymorphic and polymorphic antibody-binding epitopes. Hum Immunol (1994) 0.97
A strategy for bacterial production of a soluble functional human neonatal Fc receptor. J Immunol Methods (2007) 0.92
Effect of conformational propensity of peptide antigens in their interaction with MHC class II molecules. Failure to document the importance of regular secondary structures. J Immunol (1989) 0.87
Refolding of human class II major histocompatibility complex molecules isolated from Escherichia coli. Assembly of peptide-free heterodimers and increased refolding-yield in the presence of antigenic peptide. J Biol Chem (1994) 0.86
Modification of the carboxy-terminal flanking region of a universal influenza epitope alters CD4⁺ T-cell repertoire selection. Nat Commun (2012) 0.86
Epitopes of the NS3 protein of hepatitis C virus: recognition in HLA-DR4 transgenic mice. Immunol Cell Biol (2002) 0.80
The tetramer transformation. J Immunol (2011) 0.78
Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci (2003) 5.94
NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res (2008) 4.53
NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS One (2007) 3.99
Improved prediction of MHC class I and class II epitopes using a novel Gibbs sampling approach. Bioinformatics (2004) 3.72
NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics (2008) 3.59
Quantitative predictions of peptide binding to any HLA-DR molecule of known sequence: NetMHCIIpan. PLoS Comput Biol (2008) 2.48
Definition of supertypes for HLA molecules using clustering of specificity matrices. Immunogenetics (2004) 2.39
An integrative approach to CTL epitope prediction: a combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions. Eur J Immunol (2005) 2.19
Conflicting selective forces affect T cell receptor contacts in an immunodominant human immunodeficiency virus epitope. Nat Immunol (2006) 2.11
Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol (2005) 2.08
The frequency and immunodominance of islet-specific CD8+ T-cell responses change after type 1 diabetes diagnosis and treatment. Diabetes (2008) 2.04
Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat Immunol (2009) 1.83
NetMHCIIpan-2.0 - Improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedure. Immunome Res (2010) 1.78
MHC class II epitope predictive algorithms. Immunology (2010) 1.72
CTL epitopes for influenza A including the H5N1 bird flu; genome-, pathogen-, and HLA-wide screening. Vaccine (2006) 1.66
Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol (2013) 1.53
One-pot, mix-and-read peptide-MHC tetramers. PLoS One (2008) 1.50
Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood (2011) 1.50
NetMHCIIpan-3.0, a common pan-specific MHC class II prediction method including all three human MHC class II isotypes, HLA-DR, HLA-DP and HLA-DQ. Immunogenetics (2013) 1.49
GAD65-specific CD4+ T-cells with high antigen avidity are prevalent in peripheral blood of patients with type 1 diabetes. Diabetes (2004) 1.41
Multiple tissue-specific isoforms of sulfatide activate CD1d-restricted type II NKT cells. Eur J Immunol (2009) 1.35
Antibodies recognizing Mycobacterium avium paratuberculosis epitopes cross-react with the beta-cell antigen ZnT8 in Sardinian type 1 diabetic patients. PLoS One (2011) 1.34
HLA-B*57 Micropolymorphism shapes HLA allele-specific epitope immunogenicity, selection pressure, and HIV immune control. J Virol (2011) 1.31
Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis. Eur J Immunol (2006) 1.28
Peptide binding to HLA class I molecules: homogenous, high-throughput screening, and affinity assays. J Biomol Screen (2009) 1.27
Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B 2705-restricted CD8+ T cells. J Virol (2010) 1.26
Peptide-MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity. Eur J Immunol (2012) 1.24
HLA-A*0201-restricted CD8+ cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D. J Immunol (2008) 1.24
Major histocompatibility complex class I binding predictions as a tool in epitope discovery. Immunology (2010) 1.21
NNAlign: a web-based prediction method allowing non-expert end-user discovery of sequence motifs in quantitative peptide data. PLoS One (2011) 1.20
HLA-A*7401-mediated control of HIV viremia is independent of its linkage disequilibrium with HLA-B*5703. J Immunol (2011) 1.18
Real-time, high-throughput measurements of peptide-MHC-I dissociation using a scintillation proximity assay. J Immunol Methods (2010) 1.18
Purification of correctly oxidized MHC class I heavy-chain molecules under denaturing conditions: a novel strategy exploiting disulfide assisted protein folding. Protein Sci (2003) 1.16
Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes. Diabetes (2011) 1.13
Predicting proteasomal cleavage sites: a comparison of available methods. Int Immunol (2003) 1.12
HLArestrictor--a tool for patient-specific predictions of HLA restriction elements and optimal epitopes within peptides. Immunogenetics (2010) 1.11
Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum (2002) 1.10
Equivalent specificity of peripheral blood and islet-infiltrating CD8+ T lymphocytes in spontaneously diabetic HLA-A2 transgenic NOD mice. J Immunol (2008) 1.10
Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects. Breast Cancer Res Treat (2002) 1.07
Serum-free culture medium and IL-7 costimulation increase the sensitivity of ELISpot detection. J Immunol Methods (2008) 1.06
Beyond the hormone: insulin as an autoimmune target in type 1 diabetes. Endocr Rev (2011) 1.04
Functional recombinant MHC class II molecules and high-throughput peptide-binding assays. Immunome Res (2009) 1.03
Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother (2004) 1.02
Immunization of HLA class I transgenic mice identifies autoantigenic epitopes eliciting dominant responses in type 1 diabetes patients. J Immunol (2007) 1.01
MHCcluster, a method for functional clustering of MHC molecules. Immunogenetics (2013) 1.01
Association of HMGB1 polymorphisms with outcome in patients with systemic inflammatory response syndrome. Crit Care (2008) 1.00
HIV control through a single nucleotide on the HLA-B locus. J Virol (2012) 1.00
Association of HMGB1 polymorphisms with outcome after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2009) 0.99
Discovering naturally processed antigenic determinants that confer protective T cell immunity. J Clin Invest (2013) 0.99
Nef-specific CD8+ T cell responses contribute to HIV-1 immune control. PLoS One (2013) 0.98
acDCs enhance human antigen-specific T-cell responses. Blood (2011) 0.98
Optimization and immune recognition of multiple novel conserved HLA-A2, human immunodeficiency virus type 1-specific CTL epitopes. J Gen Virol (2003) 0.98
Critical parameters in blood processing for T-cell assays: validation on ELISpot and tetramer platforms. J Immunol Methods (2010) 0.97
Viral infection prevents diabetes by inducing regulatory T cells through NKT cell-plasmacytoid dendritic cell interplay. J Exp Med (2011) 0.97
T cells in the pathogenesis of type 1 diabetes. Curr Diab Rep (2008) 0.96
High-resolution structure of HLA-A*1101 in complex with SARS nucleocapsid peptide. Acta Crystallogr D Biol Crystallogr (2005) 0.95
Ligand binding and antigenic properties of a human neonatal Fc receptor with mutation of two unpaired cysteine residues. FEBS J (2008) 0.94
Crystal structures of two peptide-HLA-B*1501 complexes; structural characterization of the HLA-B62 supertype. Acta Crystallogr D Biol Crystallogr (2006) 0.94
Human leukocyte antigen (HLA) class I restricted epitope discovery in yellow fewer and dengue viruses: importance of HLA binding strength. PLoS One (2011) 0.94
Perceptual weights in auditory level discrimination. J Acoust Soc Am (2003) 0.93
NetMHCstab - predicting stability of peptide-MHC-I complexes; impacts for cytotoxic T lymphocyte epitope discovery. Immunology (2014) 0.93
Role of CD28 co-stimulation in generation and maintenance of virus-specific T cells. Int Immunol (2002) 0.93
Genome-based in silico identification of new Mycobacterium tuberculosis antigens activating polyfunctional CD8+ T cells in human tuberculosis. J Immunol (2010) 0.93
A strategy for bacterial production of a soluble functional human neonatal Fc receptor. J Immunol Methods (2007) 0.92
Selecting informative data for developing peptide-MHC binding predictors using a query by committee approach. Neural Comput (2003) 0.92
Qualitative and quantitative analysis of adenovirus type 5 vector-induced memory CD8 T cells: not as bad as their reputation. J Virol (2013) 0.91
Measurement of CD8 T cell responses in human type 1 diabetes. Ann N Y Acad Sci (2008) 0.91
Different binding motifs of the celiac disease-associated HLA molecules DQ2.5, DQ2.2, and DQ7.5 revealed by relative quantitative proteomics of endogenous peptide repertoires. Immunogenetics (2014) 0.91
A molecular switch in immunodominant HIV-1-specific CD8 T-cell epitopes shapes differential HLA-restricted escape. Retrovirology (2015) 0.90
Antigen-based immune therapeutics for type 1 diabetes: magic bullets or ordinary blanks? Clin Dev Immunol (2011) 0.90
Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response. PLoS One (2012) 0.90
The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling. Cancer Lett (2006) 0.90
Single-epitope DNA vaccination prevents exhaustion and facilitates a broad antiviral CD8+ T cell response during chronic viral infection. J Immunol (2004) 0.89
Differential clade-specific HLA-B*3501 association with HIV-1 disease outcome is linked to immunogenicity of a single Gag epitope. J Virol (2012) 0.89
Identification of CD8+ T cell epitopes in the West Nile virus polyprotein by reverse-immunology using NetCTL. PLoS One (2010) 0.89
Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes. PLoS One (2011) 0.89
Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy. J Immunol (2013) 0.89
Loudness enhancement: induced loudness reduction in disguise? (L). J Acoust Soc Am (2002) 0.88
Peptide-loaded dendritic cells prime and activate MHC-class I-restricted T cells more efficiently than protein-loaded cross-presenting DC. Cell Immunol (2003) 0.88
Spectral loudness summation and simple reaction time. J Acoust Soc Am (2004) 0.86
Dataset size and composition impact the reliability of performance benchmarks for peptide-MHC binding predictions. BMC Bioinformatics (2014) 0.85